Re: INFO: Medical Device Boasts Encouraging Data for Hepatitis C Treatment/Deb

[Guest guest]

Wow! I plan to hold on to this or if necessary fly to India

to get it done. This looks like a GREAT alternative if I don't clear

or relapse after treatment. I already am getting info on the stem

cell research which is available now. I am always very interested in

the non drug approach to therapy.

>

>

>

>

>

> September 26, 2008

>

> Medical Device Boasts Encouraging Data for Hepatitis C Treatment

> A medical device designed to clear viruses and immunosuppressive

proteins

> from the blood reduced Hepatitis C viral load for several people on

dialysis.

>  

> Further case studies will determine if the Aethlon Hemopurifier®

can induce a rapid virological response against Hepatitis C.

>  

>

>

> Aethlon Medical Reports Promising Treatment Results In Hepatitis-C

Infected Patients

>  

> September 21, 2008

>  

> Aethlon Medical, Inc. (OTCBB:AEMD) announced preliminary data of

Hepatitis-C (HCV) infected patients treated with the Aethlon

Hemopurifier®, a medical device designed to assist the immune

response in combating infectious disease. The HCV treated patients

were among end-stage renal disease (kidney dialysis) patients

enrolled in human safety studies being conducted at the Fortis

Hospital, in Delhi, India.

>  

> In the studies, robust viral load reductions were observed in

tested patients completing a three-treatment Hemopurifier® protocol.

The resulting data documented that two of three HCV patients tested

responded with measurable viral load reductions during the course of

three 4-hour Hemopurifier® treatments.

>  

> The three treatments were administered during scheduled dialysis

therapy every other day over the span of five days. The third patient

showed both increases and decreases in viral load during the course

of treatment, but demonstrated an overall reduction in follow-on

viral load tests. Given the small sample size, viral load data was

averaged for all 3 patients. Average initial HCV viral load was 3.13

x 108 viral units per ml of blood. After completion of three

Hemopurifier® treatments, viral load was reduced an average 57%

(final 4.1x107 IU/ml). The stepwise drop in HCV viral load averaged

36% per treatment. Follow-on testing indicated that HCV viral load

was 60% lower than initial viral load values when measured three days

after final Hemopurifier® treatment, and at seven days post

treatment, viral load declined to 82% below starting viral load

values.

>  

> Additionally, none of the patients were being treated with

antiviral drug therapy.

>  

> Viral load measurements were performed with real-time quantitative

polymerase chain reaction (RT-PCR). Control samples were measured in

duplicate while treatment samples were generally measured in

triplicate. In conclusion, the Hemopurifier® treatment of HCV

infected patients undergoing dialysis resulted in a net viral load

reduction of 60 to 80% with the effects of treatment progressing at

least 7 days beyond Hemopurifier® treatment.

>  

> " The observation of progressive viral load reduction after only

three Hemopurifier® treatments suggests that extended Hemopurifier®

treatment applications could effectively inhibit disease progression

in HCV patients, " stated Aethlon Chairman and CEO, A.

Joyce. " We now plan to further demonstrate a rapid virological

response (RVR) through a case study of an HCV patient receiving up to

four weeks of Hemopurifier® therapy. " Studies have shown that rapid

virological response (RVR) at week four is a strong predictor of

sustained virological response (SVR) in HCV patients. SVR is defined

as undetectable viral load for a minimum period of five months after

completion of treatment.

>  

> The opportunity for new antiviral strategies to fight HCV is

significant, as approximately 180 million people worldwide (3% of the

world's population) are HCV infected. According to the World Health

Organization (WHO), only 30-50% of infected patients beneficially

respond to the 48-week pegylated interferon-ribavirin treatment

standard.

>  

> The Hemopurifier® is a first-in-class medical device designed to

assist the immune response in combating infectious disease by rapidly

clearing viruses and immunosuppressive proteins from circulation. The

device provides a novel mechanism to complement antiviral therapies

by suppressing the emergence of viral strains that cause drug

resistance. The Hemopurifier® is also positioned to fill the unmet

clinical need of treating patients resistant to drug therapy or

infected by viral pathogens that are untreatable with drug and

vaccine therapy. In HCV care, the device is positioned as an adjunct

to improve clinical outcomes of the pegylated interferon-ribavirin

treatment standard. Other opportunities in HCV care include the

treatment of individuals who fail or are unable to endure standard of

care therapy, end-stage renal patients infected with HCV, and HIV

patients co-infected with HCV.

>  

> About Aethlon Medical

>  

> Aethlon Medical is the developer of the Hemopurifier®, a first-in-

class medical device designed to treat infectious disease. The

Hemopurifier® provides real-time therapeutic filtration of infectious

viruses and immunosuppressive particles, and is positioned to address

the treatment of drug and vaccine resistant viruses.

>  

> Additionally, the device holds promise in cancer care, as research

studies have verified the Hemopurifier® is able to capture

immunosuppressive particles secreted by tumors. The Hemopurifier® is

designed to act both as a stand-alone therapeutic, and as an adjunct

treatment to enhance clinical benefit of established therapies. Pre-

clinical studies conducted by researchers representing leading

government and non-government health organizations both in the United

States and abroad have documented the effectiveness of the

Hemopurifier® in capturing from circulation the viruses that

constitute pandemic threats, including H5N1 Avian Influenza (bird

flu), and Dengue Hemorrhagic Fever (DHF) from circulation. The

company is conducting studies to support the use of the Hemopurifier®

as a broad-spectrum treatment countermeasure against bioterror

threats, including Smallpox, and Ebola, Marburg, and Lassa

hemorrhagic fever.

>  

> Regulatory and commercialization initiatives in the United States

are presently focused on bioterror threats, while international

initiatives are directed toward naturally evolving pandemic threats,

and chronic infectious disease conditions including the Human

Immunodeficiency Virus (HIV) and Hepatitis-C (HCV). Aethlon

demonstrated the safety of the Hemopurifier® in a 24-treatment human

study at the Apollo Hospital in Delhi, India, and is currently

conducting further human studies at the Fortis Hospital, also located

in Delhi. The company has submitted an investigational device

exemption (IDE) to the U.S. Food and Drug Administration (FDA) to

advance the Hemopurifier® as a broad-spectrum treatment

countermeasure against category " A " bioterror threats. Additional

information regarding Aethlon Medical and its Hemopurifier®

technology is available online at http://www.aethlonmedical.com.

>  

> Certain of the statements herein may be forward-looking and involve

risks and uncertainties. Such forward-looking statements involve

assumptions, known and unknown risks, uncertainties and other factors

which may cause the actual results, performance or achievements of

Aethlon Medical, Inc to be materially different from any future

results, performance, or achievements expressed or implied by the

forward-looking statements. Such potential risks and uncertainties

include, without limitation, the Company's ability to raise capital

when needed, the Company's ability to complete the development of its

planned products, the ability of the Company to obtain FDA and other

regulatory approvals permitting the sale of its products, the

Company's ability to manufacture its products and provide its

services, the impact of government regulations, patent protection on

the Company's proprietary technology, product liability exposure,

uncertainty of market acceptance,

> competition, technological change, and other risk factors. In such

instances, actual results could differ materially as a result of a

variety of factors, including the risks associated with the effect of

changing economic conditions and other risk factors detailed in the

Company's Securities and Exchange Commission filings.

>  

> Aethlon Medical, Inc.

> URL for Article Source:

> http://www.medicalnewstoday.com/articles/122141.php

> Posted by Editors at September 26, 2008 02:54 PM

>  

> http://www.hepatitis-

central.com/mt/archives/2008/09/medical_device.html?eml=hepcen63

>